Table 3 Correlations between pre-treatment plasma fibrinogen status and clinicopathological features in breast cancer
| Â | Fib status | Â | |
|---|---|---|---|
Characteristics | Low (n = 744) | High (n = 260) | P value |
Age (years) | Â | Â | 0.268 |
  ≤ 50 | 430 (75.4%) | 140 (24.6%) |  |
  >  50 | 314 (72.4%) | 120 (27.6%) |  |
Menopausal status |  |  | <  0.001 |
 Pre/peri | 563 (77.4%) | 164 (22.6%) |  |
 Post | 181 (65.3%) | 96 (34.7%) |  |
Tumour size (cm) | Â | Â | 0.002 |
  ≤ 5 | 609 (76.3%) | 189 (23.7%) |  |
  >  5 | 135 (65.5%) | 71 (34.5%) |  |
Lymph node involvement | Â | Â | 0.943 |
 No | 270 (74.0%) | 95 (26.0%) |  |
 Yes | 474 (74.2%) | 165 (25.8%) |  |
Histological subtype | Â | Â | 0.472 |
 IDC | 717 (73.9%) | 253 (26.1%) |  |
 Non-IDC | 27 (79.4%) | 7 (20.6%) |  |
HR status | Â | Â | 0.002 |
 Positive | 475 (77.5%) | 138 (22.5%) |  |
 Negative | 269 (68.8%) | 122 (31.2%) |  |
HER2 statusa | Â | Â | 0.275 |
 Positive | 321 (75.2%) | 106 (24.8%) |  |
 Negative | 376 (72.0%) | 146 (28.0%) |  |
Ki67 index (%) | Â | Â | 0.052 |
  ≤ 14 | 209 (78.6%) | 57 (21.4%) |  |
  >  14 | 535 (72.5%) | 203 (27.5%) |  |
Clinical responder | Â | Â | 0.053 |
 CR (pCR + cCR) | 162 (81.8%) | 36 (18.2%) |  |
 PR | 349 (72.1%) | 135 (27.9%) |  |
 SD | 218 (72.4%) | 83 (27.6%) |  |
 PD | 15 (71.4%) | 6 (28.6%) |  |